(2015) Adenovirus-Mediated Over-Expression of Nrf2 Within Mesenchymal Stem Cells (MSCs) Protected Rats Against Acute Kidney Injury. Advanced Pharmaceutical Bulletin. pp. 201-208. ISSN 2228-5881
Full text not available from this repository.
Abstract
Purpose: Recent developments in the field of cell therapy have led to a renewed interest in treatment of acute kidney injury (AKI). However, the early death of transplanted mesenchymal stem cells (MSCs) in stressful microenvironment of a recipient tissue is a major problem with this kind of treatment. The objective of this study was to determine whether overexpression of a cytoprotective factor, nuclear factor erythroid-2 related factor 2 (Nrf2), in MSCs could protect rats against AKI. Methods: The Nrf2 was overexpressed in MSCs by recombinant adenoviruses, and the MSCs were implanted to rats suffering from cisplatin-induced AKI. Results: The obtained results showed that transplantation with the engineered MSCs ameliorates cisplatin-induced AKI. Morphologic features of the investigated kidneys showed that transplantation with the MSCs in which Nrf2 had been overexpressed significantly improved the complications of AKI. Conclusion: These findings suggested that the engineered MSCs might be a good candidate to be further evaluated in clinical trials. However, detailed studies must be performed to investigate the possible carcinogenic effect of Nrf2 overexpression.
Item Type: | Article |
---|---|
Keywords: | nf-e2-related factor 2(nrf2) mesenchymal stromal cells (mscs) acute kidney injury cisplatin acute-renal-failure reduces oxidative stress stromal cells growth-factor induced apoptosis cytoprotective genes endothelial-cells epithelial-cells lung injury in-vitro |
Page Range: | pp. 201-208 |
Journal or Publication Title: | Advanced Pharmaceutical Bulletin |
Journal Index: | ISI |
Volume: | 5 |
Number: | 2 |
Identification Number: | https://doi.org/10.15171/Apb.2015.028 |
ISSN: | 2228-5881 |
Depositing User: | مهندس مهدی شریفی |
URI: | http://eprints.mui.ac.ir/id/eprint/4834 |
Actions (login required)
View Item |